First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer — Stella
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(37 sites)
United States
The University of Arizona Cancer Center, Tucson, Arizona
University of California-San Diego, San Diego, California
HealthONE, Denver, Colorado
Yale University, New Haven, Connecticut
Florida Cancer Specialists, Orlando, Florida
Boca Raton Clinical Research (BRCR) Global, Plantation, Florida
University of Chicago Medical Center, Chicago, Illinois
Community Health Network, Indianapolis, Indiana
Massachusetts General Hospital, Boston, Massachusetts
Dana-Farber Cancer Institute, Boston, Massachusetts
University of Michigan, Ann Arbor, Michigan
Washington University School of Medicine St. Louis, St Louis, Missouri
Renown Regional Medical Center, Reno, Nevada
Australia
St Vincents Hospital, Sydney, New South Wales
Peter MacCallum Cancer Center, Melbourne, Victoria
The Alfred Hospital, Melbourne, Victoria
France
Centre Léon Bérard, Lyon, Auvergne-Rhône-Alpes
Institute Bergonié, Bordeaux
Gustave Roussy, Villejuif
Italy
Istituto Europeo di Oncologia IRCCS, Milan
Spain
Vall d'Hebron Instituto de Oncologia, Barcelona, Barcelona
START Barcelona, Barcelona, Catalonia
Instituto Valenciano de Oncologia, Valencia, Valencia
Institut Catala D'Oncologia - Badalona (ICO Badalona), Barcelona
START Madrid - Hospital Fundacion Jimenez Diaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
Rutgers University, New Brunswick, New Jersey
NYU Langone, New York, New York
Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York
Memorial Sloan Kettering, New York, New York
Tennessee Oncology, Nashville, Tennessee
University of Texas Southwestern Medical Center, Dallas, Texas
The University of Texas M.D. Anderson Cancer Center, Houston, Texas
University of Utah- Huntsman Cancer Center, Salt Lake City, Utah